SCSophie‐Athéna Chapron

Sophie‐Athéna Chapron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sophie‐Athéna Chapron has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin Rolland

    PSYR, CNRL, INSERM U1028, CNRS UMR5292, UCBL1 Bron France

    1 shared publication
  • Clément Dondé

    Department of Medicine University Grenoble Alpes Grenoble France

    1 shared publication
  • Frédéric Haesebaert

    Affiliations Université Claude Bernard Lyon, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, PSYR2, Bron, France, Centre Hospitalier le Vinatier, Bron, France

    1 shared publication
  • Jean-Arthur Micoulaud-Franchi

    CNRS, SANPSY, UMR 6033, University of Bordeaux, Bordeaux, France; University Sleep Clinic, University Hospital of Bordeaux, place Amélie-Raba-Léon, Bordeaux, France

    1 shared publication
  • Mikail Nourredine

    Academic Department of Addiction Medicine of Lyon (SUAL) Le Vinatier Hospital Bron France

    1 shared publication
  • Pierre Alexis Geoffroy

    Department of Psychiatry and Addictive Medicine University Hospital Bichat‐Claude Bernard, Public Hospitals of Paris Paris France

    1 shared publication

Latest Publications

  • Efficacy and safety of topiramate for reducing impulsivity: A transdiagnostic systematic review and meta‐analysis of a common clinical use

    by Sophie‐Athéna Chapron, Mikail Nourredine, Clément Dondé, Frédéric Haesebaert, Jean‐Arthur Micoulaud‐Franchi, Pierre Alexis Geoffroy, Benjamin Rolland

    Impulsivity is an important transdiagnostic feature of many psychiatric disorders, as well as a marker of poorer outcome. Topiramate is broadly used for reducing impulsivity in various neuropsychiatric disorders, but no systematic review or meta‐analysis has ever explored whether evidence supports this clinical use. We conducted a systematic review and meta‐analysis of the literature, using PubMed, PsycInfo and Cochrane databases. We included all studies assessing the efficacy of topiramate in adults with high levels of impulsivity, based on either psychometric or neuropsychological measures. Seven articles were included, involving 578 participants. Important heterogeneity in designs and quality features was observed. Topiramate lowered impulsivity levels in two of the studies that used the Barratt Impulsiveness Scale (BIS) (401 participants) and in one of the studies that used neuropsychological measures (63 participants). Four other studies found no effect of topiramate on impulsivity. A larger reduction in the BIS‐11 overall score, with a mean difference of 2.57 (95% confidence interval −4.12 to −1.02), was found in the topiramate group than the placebo group using a random effects model. However, one study accounted for the major part (85.5%) of it, and most included studies presented a high risk of bias. The use of a self‐assessment scale induced an additional risk of self‐report bias. No clear‐cut evidence was found for a transdiagnostic effectiveness of topiramate in reducing impulsivity levels. However, encouraging results were found in some specific disorders.